Analysis of serum total and free PSA using immunoaffinity depletion coupled to SRM: Correlation with clinical immunoassay tests

Journal of Proteomics

Volumn 75, Issue 15, 2012, Pages 4747-4757

  Liu, Tao ^a   Hossain, Mahmud ^a   Schepmoes, Athena A ^a   Fillmore, Thomas L ^a   Sokoll, Lori J ^b   Kronewitter, Scott R ^a   Izmirlian, Grant ^c   Shi, Tujin ^a   Qian, Wei Jun ^a   Leach, Robin J ^d   Thompson, Ian M ^d   Chan, Daniel W ^b   Smith, Richard D ^a   Kagan, Jacob ^c   Srivastava, Sudhir ^c   Rodland, Karin D ^a   Camp, David G ^a  

^a PACIFIC NORTHWEST NATIONAL LABORATORY   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d University of Texas Health Science Center   (United States)

Author keywords

Free PSA; Immunoaffinity depletion; Immunoassay; Selected reaction monitoring; Serum; Total PSA

Indexed keywords

BIOLOGICAL MARKER; PROSTATE SPECIFIC ANTIGEN; REAGENT;

ANTIBODY AFFINITY; ANTIGEN DETECTION; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CANCER DIAGNOSIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; HUMAN; IMMUNOAFFINITY CHROMATOGRAPHY; IMMUNOASSAY; LIMIT OF DETECTION; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN SYNTHESIS; SELECTED REACTION MONITORING MASS SPECTROMETRY; SENSITIVITY AND SPECIFICITY; SERUM; WORKFLOW;

BIOLOGICAL ASSAY; FEMALE; HUMANS; IMMUNOASSAY; MALE; MASS SPECTROMETRY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84864082548     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2012.01.035     Document Type: Article

References (37)

1. Sturgeon C.M., Duffy M.J., Stenman U.H., Lilja H., Brunner N., Chan D.W., Babaian R., Bast R.C., Dowell B., Esteva F.J., Haglund C., Harbeck N., Hayes D.F., Holten-Andersen M., Klee G.G., Lamerz R., Looijenga L.H., Molina R., Nielsen H.J., Rittenhouse H., Semjonow A., Shih I.M., Sibley P., Soletormos G., Stephan C., Sokoll L., Hoffman B.R., Diamandis E.P. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem 2008, 54(12):E11-E79.
2. Sturgeon C.M., Duffy M.J., Hofmann B.R., Lamerz R., Fritsche H.A., Gaarenstroom K., Bonfrer J., Ecke T.H., Grossman H.B., Hayes P., Hoffmann R.T., Lerner S.P., Lohe F., Louhimo J., Sawczuk I., Taketa K., Diamandis E.P. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers. Clin Chem 2010, 56(6):E1-E48.
3. Hanash S.M., Baik C.S., Kallioniemi O. Emerging molecular biomarkers-blood-based strategies to detect and monitor cancer. Nat Rev Clin Oncol 2011, 8(3):142-150.
4. Ludwig J.A., Weinstein J.N. Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer 2005, 5(11):845-856.
5. Meany D.L., Sokoll L.J., Chan D.W. Early detection of cancer: immunoassays for plasma tumor markers. Expert Opin Med Diagn 2009, 3(6):597-605.
6. Barry M.J. Screening for prostate cancer - the controversy that refuses to die. N Eng J Med 2009, 360(13):1351-1354.
7. Chou R, Croswell JM, Dana T, Bougatsos C, Blazina I, Fu R, Gleitsmann K, Koenig HC, Lam C, Maltz A, Rugge JB, Lin K. Screening for Prostate Cancer: A Review of the Evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2011;155(11):762-71.
8. Andriole G.L., Grubb R.L., Buys S.S., Chia D., Church T.R., Fouad M.N., Gelmann E.P., Kvale P.A., Reding D.J., Weissfeld J.L., Yokochi L.A., Crawford E.D., O'Brien B., Clapp J.D., Rathmell J.M., Riley T.L., Hayes R.B., Kramer B.S., Izmirlian G., Miller A.B., Pinsky P.F., Prorok P.C., Gohagan J.K., Berg C.D., Team P.P. Mortality results from a randomized prostate-cancer screening trial. N Eng J Med 2009, 360(13):1310-1319.
9. Schroder F.H., Hugosson J., Roobol M.J., Tammela T.L., Ciatto S., Nelen V., Kwiatkowski M., Lujan M., Lilja H., Zappa M., Denis L.J., Recker F., Berenguer A., Maattanen L., Bangma C.H., Aus G., Villers A., Rebillard X., van der Kwast T., Blijenberg B.G., Moss S.M., de Koning H.J., Auvinen A. Screening and prostate-cancer mortality in a randomized European study. N Eng J Med 2009, 360(13):1320-1328.
10. http://www.cancer.gov/cancertopics/factsheet/detection/PSA.
11. Thompson I.M., Pauler D.K., Goodman P.J., Tangen C.M., Lucia M.S., Parnes H.L., Minasian L.M., Ford L.G., Lippman S.M., Crawford E.D., Crowley J.J., Coltman C.A. Prevalence of prostate cancer among men with a prostate-specific antigen level <= 4.0 ng per milliliter. N Eng J Med 2004, 350(22):2239-2246.
12. Thompson I.M., Ankerst D.P., Tangen C.M. Prostate-specific antigen, risk factors, and prostate cancer: confounders nestled in an enigma. J Natl Cancer Inst 2010, 102(17):1299-1301.
13. Loeb S., Catalona W.J. Prostate-specific antigen in clinical practice. Cancer Lett 2007, 249(1):30-39.
14. Vessella R.L., Lange P.H., Partin A.W., Chan D.W., Sokoll L.J., Sasse E.A., Crawford E.D. Probability of prostate cancer detection based on results of a multicenter study using the AxSYM free PSA and total PSA assays. Urology 2000, 55(6):909-914.
15. Brawer M.K. Assays for complexed prostate-specific antigen and other advances in the diagnosis of prostate cancer. Rev Urol 2003, 5(Suppl. 6):S10-S16.
16. Tomlins S.A., Bjartell A., Chinnaiyan A.M., Jenster G., Nam R.K., Rubin M.A., Schalken J.A. ETS gene fusions in prostate cancer: from discovery to daily clinical practice. Eur Urol 2009, 56(2):275-286.
17. Esgueva R., Demichelis F., Rubin M.A. TMPRSS2-ERG gene fusions are infrequent in prostatic ductal adenocarcinomas. Mod Pathol 2009, 22(10):1398-1399.
18. Tomlins S.A., Aubin S.M.J., Siddiqui J., Lonigro R.J., Sefton-Miller L., Miick S., Williamsen S., Hodge P., Meinke J., Blase A., Penabella Y., Day J.R., Varambally R., Han B., Wood D., Wang L., Sanda M.G., Rubin M.A., Rhodes D.R., Hollenbeck B., Sakamoto K., Silberstein J.L., Fradet Y., Amberson J.B., Meyers S., Palanisamy N., Rittenhouse H., Wei J.T., Groskopf J., Chinnaiyan A.M. Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. Sci Transl Med 2011, 3:94.
19. Hu Y., Dobi A., Sreenath T., Cook C., Tadase A.Y., Ravindranath L., Cullen J., Furusato B., Chen Y., Thangapazham R.L., Mohamed A., Sun C., Sesterhenn I.A., McLeod D.G., Petrovics G., Srivastava S. Delineation of TMPRSS2-ERG splice variants in prostate cancer. Clin Cancer Res 2008, 14(15):4719-4725.
20. Park K., Tomlins S.A., Mudaliar K.M., Chiu Y.L., Esgueva R., Mehra R., Suleman K., Varambally S., Brenner J.C., MacDonald T., Srivastava A., Tewari A.K., Sathyanarayana U., Nagy D., Pestano G., Kunju L.P., Demichelis F., Chinnaiyan A.M., Rubin M.A. Antibody-based detection of ERG rearrangement-positive prostate cancer. Neoplasia 2010, 12(7):590-598.
21. Lange V., Picotti P., Domon B., Aebersold R. Selected reaction monitoring for quantitative proteomics: a tutorial. Mol Syst Biol 2008, 4:222.
22. Stahl-Zeng J., Lange V., Ossola R., Aebersold R., Domon B. High sensitivity detection of plasma proteins by multiple reaction monitoring of N-glycosites. Mol Cell Proteomics 2007, 6(10):1809-1817.
23. Keshishian H., Addona T., Burgess M., Kuhn E., Carr S.A. Quantitative, multiplexed assays for low abundance proteins in plasma by targeted mass spectrometry and stable isotope dilution. Mol Cell Proteomics 2007, 6(12):2212-2229.
24. Anderson N.L., Anderson N.G., Haines L.R., Hardie D.B., Olafson R.W., Pearson T.W. Mass spectrometric quantitation of peptides and proteins using Stable Isotope Standards and Capture by Anti-Peptide Antibodies (SISCAPA). J Proteome Res 2004, 3(2):235-244.
25. Addona T.A., Abbatiello S.E., Schilling B., Skates S.J., Mani D.R., Bunk D.M., Spiegelman C.H., Zimmerman L.J., Ham A.J.L., Keshishian H., Hall S.C., Allen S., Blackman R.K., Borchers C.H., Buck C., Cardasis H.L., Cusack M.P., Dodder N.G., Gibson B.W., Held J.M., Hiltke T., Jackson A., Johansen E.B., Kinsinger C.R., Li J., Mesri M., Neubert T.A., Niles R.K., Pulsipher T.C., Ransohoff D., Rodriguez H., Rudnick P.A., Smith D., Tabb D.L., Tegeler T.J., Variyath A.M., Vega-Montoto L.J., Wahlander A., Waldemarson S., Wang M., Whiteaker J.R., Zhao L., Anderson N.L., Fisher S.J., Liebler D.C., Paulovich A.G., Regnier F.E., Tempst P., Carr S.A. Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma. Nat Biotechnol 2009, 27(7):633-641.
26. Fortin T., Salvador A., Charrier J.P., Lenz C., Lacoux X., Morla A., Choquet-Kastylevsky G., Lemoine J. Clinical Quantitation of Prostate-specific Antigen Biomarker in the Low Nanogram/Milliliter Range by Conventional Bore Liquid Chromatography-Tandem Mass Spectrometry (Multiple Reaction Monitoring) Coupling and Correlation with ELISA Tests. Mol Cell Proteomics 2009, 8:1006-1015.
27. Fortin T., Salvador A., Charrier J.P., Lenz C., Bettsworth F., Lacoux X., Choquet-Kastylevsky G., Lemoine J. Multiple reaction monitoring cubed for protein quantification at the low nanogram/milliliter level in nondepleted human serum. Anal Chem 2009, 81(22):9343-9352.
28. Li Y., Tian Y.A., Rezai T., Prakash A., Lopez M.F., Chan D.W., Zhang H. Simultaneous analysis of glycosylated and sialylated prostate-specific antigen revealing differential distribution of glycosylated prostate-specific antigen isoforms in prostate cancer tissues. Anal Chem 2011, 83(1):240-245.
29. Liu T., Qian W.J., Mottaz H.M., Gritsenko M.A., Norbeck A.D., Moore R.J., Purvine S.O., Camp D.G., Smith R.D. Evaluation of multiprotein immunoaffinity subtraction for plasma proteomics and candidate biomarker discovery using mass spectrometry. Mol Cell Proteomics 2006, 5(11):2167-2174.
30. Qian W.J., Kaleta D.T., Petritis B.O., Jiang H.L., Liu T., Zhang X., Mottaz H.M., Varnum S.M., Camp D.G., Huang L., Fang X.M., Zhang W.W., Smith R.D. Enhanced detection of low abundance human plasma proteins using a tandem IgY12-SuperMix immunoaffinity separation strategy. Mol Cell Proteomics 2008, 7(10):1963-1973.
31. Kelly R.T., Page J.S., Luo Q.Z., Moore R.J., Orton D.J., Tang K.Q., Smith R.D. Chemically etched open tubular and monolithic emitters for nanoelectrospray ionization mass spectrometry. Anal Chem 2006, 78(22):7796-7801.
32. MacLean B., Tomazela D.M., Shulman N., Chambers M., Finney G.L., Frewen B., Kern R., Tabb D.L., Liebler D.C., MacCoss M.J. Skyline: an open source document editor for creating and analyzing targeted proteomics experiments. Bioinformatics 2010, 26(7):966-968.
33. Lilja H., Christensson A., Dahlen U., Matikainen M.T., Nilsson O., Pettersson K., Lovgren T. Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. Clin Chem 1991, 37(9):1618-1625.
34. Zhang W.M., Finne P., Leinonen J., Vesalainen S., Nordling S., Rannikko S., Stenman U.H. Characterization and immunological determination of the complex between prostate-specific antigen and alpha(2)-macroglobulin. Clin Chem 1998, 44(12):2471-2479.
35. Chen Z.X., Komatsu K., Prestigiacomo A., Stamey T.A. Addition of purified prostate specific antigen to serum from female subjects: studies on the relative inhibition by alpha 2-macroglobulin and alpha 1-antichymotrypsin. J Urol 1996, 156(4):1357-1363.
36. Partin A.W., Catalona W.J., Southwick P.C., Subong E.N.P., Gasior G.H., Chan D.W. Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: influence of total PSA, prostate volume, and age. Urology 1996, 48(6A):55-61.
37. Catalona W.J., Partin A.W., Slawin K.M., Brawer M.K., Flanigan R.C., Patel A., Richie J.P., deKernion J.B., Walsh P.C., Scardino P.T., Lange P.H., Subong E.N.P., Parson R.E., Gasior G.H., Loveland K.G., Southwick P.C. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease - a prospective multicenter clinical trial. JAMA 1998, 279(19):1542-1547.